RTP Mobile Logo

In these audio proceedings from one-on-one interviews conducted by Dr Neil Love, the invited medical oncologist and registered nurse provide oncology nurses with therapeutic strategies to address the disparate needs of patients with multiple myeloma. This content is available in a number of formats for listening on the go with a mobile device or in the office or at home on a computer.

   
FACULTY: EDITOR:
Kenneth C Anderson, MD
Kraft Family Professor of Medicine
Harvard Medical School
Chief, Division of Hematologic Neoplasia
Director, Jerome Lipper
Multiple Myeloma Center
Director, LeBow Institute
for Myeloma Therapeutics
Dana-Farber Cancer Institute
Boston, Massachusetts
Jacy Spong, RN, BSN, OCN
Mayo Clinic Scottsdale
Scottsdale, Arizona
Neil Love, MD
Research To Practice
Miami, Florida
     
INTERVIEW WITH DR ANDERSON
  • Extending progression-free and overall survival in MM during the era of novel agents
  • Current era of MM treatment with proteasome inhibitors — bortezomib, carfilzomib and MLN9708 — and immunomodulatory drugs (IMiDs) — lenalidomide and pomalidomide
  • Role of autologous stem cell transplant in the era of novel agents
  • Maintenance therapy after initial induction treatment for transplant-ineligible patients
  • Post-transplant maintenance lenalidomide and second primary cancers
  • Preferred options for pretransplant doublet and triplet induction regimens
  • Tolerability and side effects of lenalidomide
  • Bortezomib-related side effects – Subcutaneous administration and weekly dosing to ameliorate neuropathy
  • Benefits of the irreversible proteasome inhibitor carfilzomib in relapsed, refractory MM and the lack of associated peripheral neuropathy
  • Side effects of carfilzomib
  • Incorporation of carfilzomib into up-front induction therapy regimens — Carfilzomib/ lenalidomide/ dexamethasone
  • Efficacy and side effects of the third-generation IMiD pomalidomide
  • Etiology and management of renal failure in patients with MM
  • Prevalence of peripheral neuropathy in MM at initial diagnosis
  • Prevention of lytic bone disease and fractures with bisphosphonates
  • Duration of bisphosphonate therapy for patients with active myeloma
  • Bisphosphonate-associated osteonecrosis of the jaw (ONJ)
     
INTERVIEW WITH MS SPONG
  • Case discussion: A 69-year-old man with MM and significant bone pain receives CyBorD
    – Use of subcutaneous bortezomib administration
    – Post-transplant maintenance lenalidomide therapy
    – Prevention of lenalidomide-associated thrombosis
    – Side effects of pomalidomide
    – Family support and patient coping with myeloma and its treatment
  • Case discussion: A 54-year-old man with IgG kappa smoldering myeloma for several years develops active, indolent myeloma and receives cyclophosphamide, carfilzomib, thalidomide and dexamethasone on the CYCLONE trial
    – Efficacy and side effects of carfilzomib
  • Case discussion: An 87-year-old man has smoldering myeloma for 2 decades before developing active myeloma with significant renal failure and anemia
    – Lenalidomide-associated rash
    – Initiation and duration of bone-targeted treatment for MM
    – Prophylaxis for ONJ